Loading…
VENTOLIN RESPIRATOR is a brand name for Albuterol (also known as Salbutamol). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Ventolin Respirator Solution is indicated in adults, adolescents and children aged 4 to 11 years. For babies and children under 4 years of age, see Section
Verbatim from this product's MHRA label. Tap a section to expand.
2. Ventolin Respirator Solution is indicated for use in the routine management of chronic bronchospasm unresponsive to conventional therapy, and in the treatment of acute severe asthma. 2 Posology and method of administration Ventolin Respirator Solution is for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser.
The solution should not be injected or swallowed. Ventolin Respirator Solution may be administered intermittently or continuously. Salbutamol has a duration of action of 4 to 6 hours in most patients. Private purchase of nebuliser devices for use at home to deliver rescue therapy for the acute treatment of asthma in children and adolescents is not recommended.
Only specialists in respiratory medicine should initiate and clinically manage use of nebulisers and associated nebulised medicines at home for acute treatment of asthma in children and adolescents. Children should be trained in the correct use of their device to deliver rescue therapy and use should be supervised by a responsible adult.
Urgent medical assistance should be sought if worsening asthma symptoms are not relieved by rescue medicines, even if there is short-term recovery following use of prescribed nebulised medication. 5 mg of salbutamol) should be diluted to a final volume of 2 ml with sterile normal saline.
5 ml. The resulting solution is inhaled from a suitably driven nebuliser until aerosol generation ceases. Using a correctly matched nebuliser and driving source this should take about ten minutes. Ventolin Respirator Solution may be used undiluted for intermittent administration.
For this, 2 ml of Ventolin Respirator Solution (10 mg of salbutamol) is placed in the nebuliser and the patient allowed to inhale the nebulised solution until bronchodilation is achieved. This usually takes 3 - 5 minutes. Some adult patients may require higher doses of salbutamol up to 10 mg, in which case nebulisation of the undiluted solution may continue until aerosol generation ceases.
Paediatric Population The same mode of administration for intermittent administration is also applicable to children. 5 ml with sterile normal saline. Some children (over the age of 18 months) may, however, require higher doses of salbutamol up to 5 mg.
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000). Very common and common events were generally determined from clinical trial data.
Rare, very rare and unknown events were generally determined from spontaneous data.
IImmmmuunnee ssyysstteemm ddiissoorrddeerrss Very rare:
Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse MMeettaabboolliissmm aanndd nnuuttrriittiioonn ddiissoorrddeerrss Rare: Hypokalaemia. Potentially serious hypokalaemia may result from beta2 agonist therapy.
4) NNeerrvvoouuss ssyysstteemm ddiissoorrddeerrss Common: Tremor, headache.
Very rare:
Hyperactivity.
CCaarrddiiaacc ddiissoorrddeerrss Common:
Tachycardia. 4) VVaassccuullaarr ddiissoorrddeerrss Rare: Peripheral vasodilatation. RReessppiirraattoorryy,, tthhoorraacciicc aanndd mmeeddiiaassttiinnaall ddiissoorrddeerrss Very rare: Paradoxical bronchospasm.
GGaassttrrooiinntteessttiinnaall ddiissoorrddeerrss Uncommon:
Mouth and throat irritation. MMuussccuulloosskkeelleettaall aanndd ccoonnnneeccttiivvee ttiissssuuee ddiissoorrddeerrss Uncommon: Muscle cramps. * reported spontaneously in post-marketing data therefore frequency regarded as unknown Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.
Ventolin Respirator Solution must only be used by inhalation, to be breathed in through the mouth, and must not be injected or swallowed. Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma.
Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death. Physicians should consider using the maximum recommended dose of inhaled corticosteroid and/or oral corticosteroid therapy in these patients.
Patients receiving treatment at home should be warned to seek medical advice if treatment with Ventolin Respirator Solution becomes less effective. As there may be adverse effects associated with excessive dosing the dosage or frequency of administration should only be increased on medical advice.
Patients being treated with Ventolin Respirator Solution may also be receiving other dosage forms of short-acting inhaled bronchodilators to relieve symptoms. , inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Ventolin Respirator Solution.
Increasing use of bronchodilators, in particular short-acting inhaled β2-agonists, to relieve symptoms, indicates deterioration of asthma control, and patients should be warned to seek medical advice as soon as possible. The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective, or more inhalations than usual are required.
g. higher doses of inhaled corticosteroid or a course of oral corticosteroid). Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.
, daytime symptoms, night-time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol. Severe exacerbations of asthma must be treated in the normal way.
1. Non-IV formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Albuterol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Intermittent treatment may be repeated up to four times daily.
Children aged 12 years and over:
Dose as per adult population. In infants under 18 months the clinical efficacy of nebulised salbutamol is uncertain. As transient hypoxaemia may occur supplemental oxygen therapy should be considered. Other pharmaceutical forms may be more appropriate for administration in children under 4 years old.
Continuous administration Ventolin Respirator Solution is diluted with sterile normal saline to contain 50-100 micrograms of salbutamol per ml, (1-2 ml solution made up to 100 ml with diluent). The diluted solution is administered as an aerosol by a suitably driven nebuliser.
The usual rate of administration is 1- 2 mg per hour.
Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease.
Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin. Ventolin Respirator Solution should be used with care in patients known to have received large doses of other sympathomimetic drugs.
Potentially serious hypokalaemia may result from β2-agonist therapy, mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics.
Serum potassium levels should be monitored in such situations. In common with other β-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported.
Concurrent administration of corticosteroids can exaggerate this effect. 8). Increase in lactate levels may lead to dyspnoea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting beta-agonist treatment.
It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting. A small number of cases of acute angle-closure glaucoma have been reported in patients treated with a combination of nebulised salbutamol and ipratropium bromide.
A combination of nebulised salbutamol with nebulised anticholinergics should therefore be used cautiously. Patients should receive adequate instruction in correct administration and be warned not to let the solution or mist enter the eye.
Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. 1 mg/ml Benzalkonium chloride in each dosage unit. Benzalkonium chloride may cause bronchospasm, especially in patients with asthma. As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.
This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator. Ventolin Respirator Solution should be discontinued immediately, the patient assessed, and if necessary a different fast-acting bronchodilator instituted for on-going use.